Thanks To Encouraging Data, These Mid-Cap Stocks Layout $300M Equity Raise
POINT Biopharma Global Inc (NASDAQ:PNT) priced its public offering of 13.9 million shares at $9.00 per share, with gross proceeds…
Benzinga’s Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades
For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low of $2.89. Moreover, at the end of the last trading period, the closing price was at $4.26.
Berenberg Initiates Coverage On POINT Biopharma Global with Buy Rating, Announces Price Target of $20
Berenberg analyst Zhiqiang Shu initiates coverage on POINT Biopharma Global (NASDAQ:PNT) with a Buy rating and announces Price Target of $20.
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday’s Mid-Day Session
Gainers
Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares jumped 70.4% to $39.37 after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
POINT Biopharma Shares Jump After Updated Efficacy, Safety Data From Prostate Cancer Candidate
POINT Biopharma Global Inc (NASDAQ:PNT) shared updated efficacy and safety data from the 27-patient lead-in cohort for the Company’s phase 3…
Peering Into POINT Biopharma Global’s Recent Short Interest
POINT Biopharma Global's (NASDAQ:PNT) short percent of float has fallen 3.57% since its last report. The company recently reported that it has 12.90 million shares sold short, which is 17.56% of all regular shares that are available for trading.
Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday
Gainers
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.
